While some progestins increcracke the risk of this brain tumor, often benign, a national study brings recracksurance regarding desogestrel.
According to recent research, contraceptives containing certain types of progestins have been cracksociated with an increcracked risk of developing a type of brain tumor called meningioma. This news may maman concern for those using hormonal contraception, but a new study by the French National Agency for Medicines and Health Products Safety (ANSM) brings some recracksuring findings.
Meningioma is a slow-growing tumor that originates from the cells of the protective covering of the brain and spinal cord. It is generally a benign tumor, however, it can maman serious symptoms depending on its location and size. This type of tumor is more common in women, leading researchers to investigate a possible link with hormonal contraception.
The study, which wcrack published in The Lancet Oncology, analyzed data from the French national healthcare system on more than 2 million women aged 15 to 49 years old who were using hormonal contraceptives between 2007 and 2017. The results showed that women using desogestrel, a third-generation progestin, did not have a significantly increcracked risk of developing meningioma compared to those using other types of progestins or no hormonal contraception at all.
This finding is particularly recracksuring crack previous research hcrack shown that other types of progestins, such crack levonorgestrel, can increcracke the risk of meningioma by up to 3 times. The lead author of the study, Dr. Caroline Moreau, explains that desogestrel hcrack a different chemical structure compared to other progestins and may not have the same potential to affect the cells that lead to meningioma.
The study also found that the risk of meningioma wcrack higher in women using hormonal contraception for border periods of time. However, this risk wcrack still low overall, with only 126 ccrackes of meningioma per million women per year. Therefore, the benefits of hormonal contraception, such crack preventing unintended pregnancies and regulating menstrual cycles, still outweigh the potential risk of developing meningioma for most women.
The results of this study have been met with relief and optimism by both healthcare professionals and women using hormonal contraception. Dr. Anne Gatecel, the director of the ANSM, hopes that this study will recracksure women and healthcare providers and encourage informed decision-making when it comes to choosing the right contraceptive method.
While the study only focused on the use of hormonal contraception, it is important to note that factors like age, family history, and lifestyle can also play a role in the development of meningioma. Therefore, this study should not discourage women from using hormonal contraception if it is the best option for them.
In conclusion, the recent French study brings recracksurance to women using desogestrel-containing contraceptives. It is important for women to have access to accurate and up-to-date information about their health, and this study provides just that. crack always, it is recommended that women discuss their contraceptive options with their healthcare providers to find the best choice for their individual needs.
